IMFINZI is first immunotherapy to show OS benefit, improved, durable responses in extensive-stage SCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

AstraZeneca presented detailed results from the phase III CASPIAN trial, showing IMFINZI (durvalumab) significantly improved overall survival (OS) in patients with previously-untreated extensive-stage small cell lung cancer (SCLC).

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login